C07C 281/10
The carbon atom being further bound to an acyclic carbon atom or
Official title: the carbon atom being further bound to an acyclic carbon atom or to a carbon atom of a ring other than a six-membered aromatic ring
C07C281/10 (The carbon atom being further bound to an acyclic carbon atom or) appears on 26 US grants and 9 published applications in this corpus.
Search patents in C07C- Granted patents
- 26
- Published applications
- 9
- Assignees
- 10
- Inventors
- 41
- Latest grant
- 7 Jun 2016
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 3 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 2 | 1 |
| 2007 | 1 | 0 |
| 2008 | 1 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 1 |
| 2015 | 2 | 1 |
| 2016 | 2 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex7 Jun 2016US 9,359,289 B2Intrexon Corporation
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex9 Feb 2016US 9,255,273 B2Intrexon Corporation
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex27 Oct 2015US 9,169,210 B2Intrexon Corporation
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex11 Aug 2015US 9,102,648 B1Intrexon Corporation
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex3 Sep 2013US 8,524,948 B2Intrexon Corporation
- Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex11 Feb 2016US 2016/0039750 A1Intrexon Corporation
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex27 Aug 2015US 2015/0240244 A1Intrexon Corporation
- Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex13 Feb 2014US 2014/0045903 A1Intrexon Corporation
- Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex14 Feb 2013US 2013/0040389 A1Intrexon Corporation
- Bioavailable Diacylhydrazine Ligands for Modulations the Expression of Exogenous Genes via an Ecdysone Receptor Complex7 Feb 2013US 2013/0035487 A1Intrexon Corporation
Most cited
By later US patents
- Inhibitors of thrombosis48US 5,492,895 ACorvas International, Inc. · 1996
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex45US 7,456,315 B2Intrexon Corporation · 2008
- Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex21US 7,563,928 B2Intrexon Corporation · 2009
- Fused benzeneoxyacetic acid derivatives20US 5,344,836 AOno Pharmaceutical Co., Ltd. · 1994
- Dipeptide derivative and prophylactic and therapeutic agent for bone diseases containing the same18US 5,395,824 ASuntory Limited · 1995